Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Path 19.01 and 19.07 > 19.07.04 Assessment of tests > Flashcards

19.07.04 Assessment of tests Flashcards

1
Q

Why is it important to assess performance of genetic tests

A

Due to increased availability of tests, important to assess performance for clinical and public health practice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is ACCE framework

A
  • Analytic validity
  • Clinical validity
  • Clinical utility
  • Ethical, legal and social implications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is analytical validity

A

How accurately and reliably the test measures the genotype of interest. Based on data from labs: method, validation process, sensitivity, specificity, reliability and reproducibility.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is clinical validity

A

How consistently and accurately the test detects or predicts the intermediate of final outcomes of interest.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a clinical positive predictive value

A

Probability of having/ developing the disease with a positive test results. Penetrance?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is a clinical negative predictive value

A

Probability of NOT having/not developing the disease with a negative test results. Locus/allelic heterogeneity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is clinical sensitivity

A

Probability of a positive result when the condition is known to be present. Will be reduced if there is locus/allelic heterogeneity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is clinical utility

A

How likely the test is to significantly improve patient outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How can genetic testing improve patient outcomes

A
  • Aids diagnosis. Avoids invasive/expensive tests. e.g.g muscle biopsy in DMD.
  • Could lead to altered treatment: F508del or G551D in CF and Ivacaftor drug.
  • Aids prognosis and managements. ATM mutation carriers avoid X-rays.
  • Presymptomatic testing in other family members. Could lead to early disease detection (hereditary cancer predispositions)
  • Genetic risk assessment: reduce the need for clinical tests in family members that have tested negative for variant.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Who developed the ACCE framework

A

CDC’s (Centre of disease control and prevention, in the USA) Office of Public health genomics (OPHG)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Purpose of framework

A

It is a process to allow policy makers to see data about DNA testing, to enable decision making. Helps to identify gaps in knowledge that will help define future research agendas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is UKGTN

A

UK Genetic testing network. An advisory organisation that provided commissioning support to NHS and Department of health. No longer active (since 2018).
Will be continued after restructuring of genetic services in NHS England.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Purpose of UKGTN

A

To ensure equity of access to genetic testing. Acts as a coordinated body that identifies lab services (directory of all tests offered), has a criteria for labs to be a member (accredited), evaluates new services (gene dossiers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is UKGTN CSAG

A

Clinical and Scientific advisory group. Acts in a commisionary advisory capacity to influence national policy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does the GTEWG do?

A

Genetic test evaluation working group. Evaluates gene dossiers and passes successful ones on to CSAG for ratification and then to commissioners to fund tests.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What other working groups work with CSAG

A
  • Rare disease service improvement working group
  • Lab membership and audit working group
  • Development working group
17
Q

What are UKGTN gene dossiers

A

Means of evaluating genetic tests offered by labs nationally. Ensures they are scientifically valid and clinically useful

18
Q

What framework is the gene dossier based on

A

ACCE- analytic validity, clinical validity, clinical utility, ethical/legal and social implications.

19
Q

What is EGAPP

A

Evaluation of Genomic applications in practice and prevention

20
Q

Who initiated EGAPP and when

A

2004 by CDC (Centre for disease control and prevention).

21
Q

Purpose of EGAPP

A

To establish and test a systematic, evidence-based process for evaluating genetic tests. Also evaluates other technology that are transitioning from research to clinical/public health practice

22
Q

What does the EGAPP working group do

A

Established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of newly emerging genetic tests for clinical practice. Highlights gaps in knowledge and guidance on appropriate use of tests in a specific clinical scenario

23
Q

What is NIHCE

A

National Institute for Health and Clinical Excellence- aka NICE.

24
Q

When was NICE established and why

A

Set up in 1999, to reduce variation in the availability and quality of NHS treatments and care. In 2013 NICE became a Non-Departmental Public Body (NDPB).

25
Q

What does NICE do

A

Develop evidence-based guidance and quality standards in social care. Accountable to Department of Health, but independent to government. Guidance is officially for England only.

26
Q

Examples of NICE guidance on genetic tests

A

Autism- using arrayCGH testing. Melanoma assessment and management- when is genetic testing appropriate

27
Q

Examples of quality standards provided by NICE

A

Quality standard for Breast cancer. Indicates when a treatment/procedure is considered highly effective, cost effective and safe

28
Q

Example of technology appraisal by NICE

A

Looks at drugs and devices, ensures equitable access across country. e.g. Trastuzumab in people with tumours expressing HER2 (human epidermal growth factor receptor 2)

29
Q

What does Diagnostics and medical technologies programme do

A

Evaluate medical diagnostics, access to new technologies/devices on NHS

30
Q

Purpose of Interventional guidance

A

Evaluates the safety and efficacy of procedures used for diagnosis or treatment

31
Q

What is Diagnostics assessments programme (DAP)

A

Helps to develop guidelines to ensure NHS is able to adopt clinically and cost effective technologies rapidly and consistently.

Path 19.01 and 19.07 (45 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions